SUMMARY Throughout our professional lifetimes, we are conditioned by the need to choose: among careers, among treatments for our patients, among health habits and lifestyles. After detailing the extent to which a choice-making orientation has dominated our lives, our society, our health system, our science, this paper describes areas in which it is crucial that choices not be made. These include the choice between basic and applied research, between targeted and investigator-initiated research, between prevention and treatment of cardiovascular disease, and between the need to know (research on mechanisms of disease) and the need to take action (intervention in the individual and the community to control disease). In each of these areas, a decision to emphasize either alternative at the expense of the other is undesirable and defeats the basic goals of understanding and controlling heart and vascular disease.
THE 1980s began with uncertainty. We have made major progress toward the conquest of cardiovascular diseases. To our remarkable achievements at the laboratory bench, we can add major accomplishments in the translation of fundamental research findings into community programs that are effective -programs that work. Yet, the sobering fact is that improved health for our people is not a national priority. We live in a nation that believes it is the victim of forces weakening the economy and the national security, thereby threatening its position of world leadership. I do not argue the validity of these assumptions, but simply observe that they dominate the formation of public policy, leaving little room for concern about the conquest of major diseases.
In response to the low priority assigned to health, we might attempt to fuse a concern for cardiovascular diseases with the national preoccupation over economic issues. We might argue, as does the recent excellent report of the working group on arteriosclerosis of the National Heart, Lung, and Blood Institute,' that heart and vascular diseases cost this country billions of dollars each year, not only in direct expenses of medical care, but-also in costs attendant to lost productivity.
But in a climate characterized by a fixation on dollars, this approach is likely to result simply in greater atten-tion to the containment of costs of hospital and medical care and on a reduction in employee health benefit programs and workmen's compensation rather than on the underlying causes of the problem, the disease processes themselves.
How do we confront this gloomy public policy situation? I believe there are two ways to do this -a bad way and a good way. The bad way is to be attracted away from our game plan, to be tempted to become amateur economists, federal policy makers or politicians. Our purpose is not economics, public policy, or politics. Our purpose, our talents, our training and our instincts are directed toward better understanding and control of diseases of the heart and blood vessels, leading to reduction of premature death and illness.
These comments should not be interpreted as a criticism of the American Heart Association's public policy posture, the development of its Washington office, or the attempt to maintain communication with the real power structure in this country. That attempt has produced benefits and it will continue to produce benefits, particularly if it concentrates on what I consider to be the good approach to the dilemma.
How can we continue to make progress in the conquest of these killer diseases? In my opinion, by the direct approach. By doing the necessary research, by translating research into improved practice, by developing and implementing community programs in cardiovascular disease control, by speaking directly to the victims of these diseases, the general public. These activities are, after all, what we are trained to do and what we do best. Furthermore, our credibility with the public and with the professional community is our most precious asset. The public, in turn, with our sup-port, will continue to exert its influence on the policy makers. And ultimately, the policy makers must listen.
Along this road we will face choices. Some of these choices will be of our own making and some will be externally imposed. I want to discuss choices, particularly choices that must not be made.
We've become accustomed to choosing. Choosing a school, a career, a mate, a home, a diagnosis, a treatment, a lifestyle, a diet, a physician, a government. We are constantly confronted with problems attendant to limited resources, whether managing our own budget or that of an organization. We respond to the problem of allocating limited resources by adopting a system of priorities. Priorities are nothing but choices. We choose to spend money on priority item A before spending it on item B. But, if we are not careful, we may be forced into choice-making situations in which choice is neither possible nor desirable.
There are choices that we must never be led to make: the choice between basic and applied research, the choice between targeted and investigator-initiated research, the choice between prevention and treatment-of disease, and the choice between the need to know and the need to act. ducted by the federal government. Nothing could be further from the truth. My experience does not permit informed comment about all medical funding entities within the federal government, but the NHLBI has sought and followed informed opinion from the investigative community in conducting its program initiatives. The argument that a better or more far-reaching result could have been reached if a single investigator had initiated and conducted the HDFP cannot be defended. I doubt that any of us associated with this program would have serious criticism of the basic process followed by the NHLBI.
But targeting canot be generalized to all areas of research. We must protect the individual investigator following his or her own scientific conscience, attentive to leads generated by his or her prior investigations, and responsive to his or her own fundamental intellectual curiosity. In a democracy, we place high value on the free flow of ideas, whether economic, political or scientific. Furthermore, as the cancer chemotherapy program demonstrates, we cannot program innovation. We cannot say to an investigator or even to a group of investigators, Here is the money, now go out and make a scientific breakthrough. We must guarantee through diverse and adequate funding of the best ideas of the best investigators a steady flow of basic research results, initiated by individual scientists. The Choice Between Prevention and Treatment Many of us were pleasantly surprised by Richard Ross's presidential address to the American Heart Association in 1974. 13 In this address, Dr. Ross outlined his personal transition in philosophical approach to cardiology and medicine. He said, "Today's physician has a responsibility to his individual patients who are by and large the symptomatic patients in the later stages of their disease, but he also has an obligation to the rest of the population who have not yet developed symptomatic severe disease. He must work by whatever means are required to prevent the development of atherosclerosis and retard its progress in the population as a whole."
It makes basic sense that prevention is less costly than treatment. If we are truly interested in cost containment in medical care, what better way to contain costs than to avoid them altogether by keeping potential patients healthy and out of the hospital. But cost containment is not our most important concern. Preventive strategies lead to a higher quality of life as well as to a longer life. The lifestyle interventions reflected in the American Heart Association's program of risk factor control produce life of higher quality. The cigarette addict may not agree with us, at least as he or she is moving through the throes of withdrawal, but there can be little doubt that the unhooked exsmoker has a higher quality of life as a result of kicking the habit. There can be no doubt that the Mediterranean diet, long advocated by Stamler, Blackburn, Keys and their associates, is both highly palatable, highly nutritious, and altogether rather classy.
Furthermore, our prevention and intervention technology is improving dramatically. What we used to call health education has now become a much more sophisticated program of health behavioral change involving an alliance between a teacher providing individual techniques and skills and a learner truly motivated to improve his or her lifestyle in a manner consistent with increased vigor, increased happiness, fewer medical bills, and longer life. Consider some examples. The Multiple Risk Factor Intervention Trial (MRFIT) recently reported"4 that of 4103 MRFIT special intervention participants who were smokers at the first screening visit, 46% said that they were not cur-rently smoking cigarettes 48 months after entry to the trial. These results were more favorable than initially anticipated in the design. Data on changes in lifestyle of adult Americans indicate lower frequency of cigarette smoking, reduced intake of butter fat, lard and eggs, and increased frequency of detection, treatment and control of high blood pressure. 7 The comment that preventive and interventive strategies do not work is simply unjustified in the light of recent experience using modem intervention techniques.
Deaths from coronary heart disease in this country have fallen, both in percentage and absolute number. We are, for the first time in many years, observing fewer than 1 with Ross that there is no real cure for the most dramatic manifestations of cardiovascular disease. 13 Prevention and treatment are under dynamic tension. As our therapeutic discoveries proliferate, there is the danger that the public will be lulled away from a healthy lifestyle consistent with disease prevention in the false belief that they should not worry, the miracles of modem medicine can fix them up if something goes wrong. We must maintain an emphasis both on the prevention of disease and on the treatment of that disease. We run the risk of deemphasizing prevention in favor of costly treatment and unfortunately, our most common system of paying for health care is partly to blame. Third-party payers seldom reimburse for prevention or intervention programs. On the other hand, if our attraction to preventive strategies becomes entirely economic, there will be a problem. We must again recognize that our goal is highest possible quality of life. Finally, we must worry that the decline in cardiovascular mortality will be interpreted by policy makers as indicating that the battle is over and we have won. Cardiovascular disease is still our number 1 killer. More people continue to die in this country each year from cardiovascular disease than from all other causes combined. Another choice that must not be made: prevention vs treatment.
The Choice Between the Need to Know and the Need to Act We must have an uninterrupted flow of facts and information to guide the formulation of public programs in the prevention and treatment of cardiovascular disease. Research must continue. But at an appropriate time, we must make recommendations for public programming and action. There is, as noted earlier, no such thing as total or perfect knowledge. A relatively safe and efficacious smallpox vaccination was available before the smallpox virus or any other infectious microorganism had been identified. British sailors were prevented from developing scurvy long before the identification of vitamin C. Hypertensives with relatively modest elevations of diastolic blood pressure can profit from blood pressure reduction by pharmacologic intervention, even though we rarely have any idea what caused their blood pressure to become high in the first place. It is almost always true in programming for disease control in the general population that we must act before complete knowledge is available. Louis Katz,'7 speaking as Duff lecturer for this Association in 1970 stated, "How complete must knowledge be before it is applied in developing a prevention program? I believe it is not essential to have every t crossed and every i dotted. When the shape of the program becomes fairly clear from the state of developing knowledge, then the value of the prevention program should be explored. The particular program may have to be modified or dropped as new knowledge appears, just as unexpected problems arising during the course of applying the prevention program may lead to these possibilities." Yet, as Katz also says, this is no excuse for recklessness, no excuse for delaying or deemphasizing continued acquisition of research knowledge. Upon the introduction of com-munity intervention programs, it is important to evaluate these programs to determine their safety and effectiveness in mass application. Another choice that must not be made -the choice to continue to develop new knowledge, the need to know, and the choice to apply that knowledge through public programming, the need to act.
In conclusion, we have looked at choices and choice-making behavior. We have considered areas in which choices must be made and areas in which choices must not be made. Our great goal of improved health for all members of the population through the reduction of premature mortality and unnecessary morbidity from heart and vascular disease requires an emphasis not necessarily consistent with current public policy. By working together, by emphasizing good research, both basic and applied, both targeted and investigator-initiated, both public and private, we can avoid a posture which may make us not only less than we need to be but less than we are. The best way to continue to serve the public and its health and to continue the impressive gains toward the conquest of cardiovascular disease is to refuse to make choices that must not be made.
